Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

New hope for acute leukemia patients…

In a Phase II clinical trial, Annamycin was given to patients who had failed an average of five previous induction therapy attempts, and 37% of those patients cleared enough of their leukemic cells to qualify for a bone marrow transplant.  This kind of performance, if repeated in a larger clinical trial, could make Annamycin a potential blockbuster new drug.  And, Annamycin’s unique lack of cardiotoxicity could be a game-changer for pediatric patients.

To find out why, click here.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates regarding Moleculin and breakthrough Cancer related innovations!

You have Successfully Subscribed!